Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- February15 2004
- Volume 11
- Issue 3
Doc's Success Factors
Author(s)Michael Sheehan
Advertisement
The Millionaire Next Door
The Millionaire Mind
Dr. Thomas Stanley, author of the bestsellers (Pocket Books; 1998) and (Andrews McMeel Publishing; 2001), has surveyed thousands of wealthy and successful people over the years. In one survey he asked physicians what are the “very important†factors in being a successful person. Here are the surprising results:
Articles in this issue
about 18 years ago
Select the Right Option for Your Moneyabout 18 years ago
Ease Retirement with a Reverse Mortgageabout 18 years ago
Manage Annuities to Improve Retirementabout 18 years ago
Narrow the Hunt for a Financial Advisorabout 18 years ago
Give Yourself the Gift of Independenceabout 18 years ago
Mull the Benefits of Loan Consolidationabout 18 years ago
Don't Squander What's in the Piggy Bankabout 18 years ago
Move Your Estate Plan into Action Todayabout 18 years ago
Spread Your Investor Wings Far and Wideabout 18 years ago
Exercise Caution with Home Equity LoansAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5